Growth Factors of Neurodegenerative Diseases Drugs Market
The neurodegenerative diseases drugs market size was valued at USD 35,497.3 million in 2018, and the market is now projected tgrow from USD 94,260.7 million by 2032, exhibiting a CAGR of 7.1% during the forecast period of 2023-2030.
Sales have mainly led Biogen neurodegenerative diseases drugs market growth from Tecfidera, the introduction of SPINRAZA, and strategic partnerships. Novartis AG is projected tgain the largest market share due tGilenya's demand and NICE's recommendation for Extavia. Key players include Pfizer, Merck, Sanofi, Teva, and UCB. Competition in the market is still stiff with players such as Lundbeck, Mitsubishi Tanabe, and ACADIA.
Comprehensive Analysis of Neurodegenerative Diseases Drugs Market
The neurodegenerative diseases drugs market and healthcare industry is rising at an exponential rate due tits market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by Drug Class, by Disease Indication and by Route of Administration. The Drug Class include, Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others. The Disease Indication includes, Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others. The Route of Administration includes, Route of Administration.
The North American drug market for neurodegenerative diseases had a maximum turnover of USD 18,174.6 million during 2018. Favorable health reimbursement policies further boost market growth. The region is expected tmaintain its lead throughout the forecast period.
The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Biogen, Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Pharma, UCB S.A., ACADIA Pharmaceuticals Inc., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation and Other players.. These market players provide a level-playing competitive landscape.
In March 2019, The FDA recently approved Mayzent, an immunomodulator developed by Novartis AG, for use in the relapsing forms of multiple sclerosis (RMS).
Segmentation Table
Global Portable Ultrasound Market Scope
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Disease Indication
Multiple Sclerosis
Parkinson’s Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Others
By Route of Administration
Oral
Injection
Transdermal
By End User
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America (USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
Latin America (Brazil, Mexicand Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. 3.4 Market Trends
- 5. Key Insights
- 6. 4.1 Prevalence ofNeurodegenerative Diseases - For Key Countreis, 2018
- 7. 4.2 Regulatory Scenario - For KeyCountries
- 8. 4.3 Patent Snapshot
- 9. 4.3 New Product Launch
- 10. 4.4 Pipeline Analysis
- 11. 4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships
- 12. 5. GlobalNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 13. 5.1. Key Findings / Summary
- 14. 5.2. Market Analysis, Insightsand Forecast – By Drug Class
- 15. 5.2.1Immunomodulators
- 16. 5.2.2Interferons
- 17. 5.2.3Decarboxylase Inhibitors
- 18. 5.2.4 DopamineAgonists
- 19. 5.2.4 Others
- 20. 5.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 21. 5.3.1 MultipleSclerosis
- 22. 5.3.2Parkinson’s Disease
- 23. 5.3.3Alzheimer's Disease
- 24. 5.3.4 SpinalMuscular Atrophy (SMA)
- 25. 5.3.5 Others
- 26. 5.4. Market Analysis, Insightsand Forecast – By Route of Administration
- 27. 5.4.1 Oral
- 28. 5.4.2Injection
- 29. 5.4.3Transdermal
- 30. 5.5. Market Analysis, Insightsand Forecast – By Distribution Channel
- 31. 5.5.1 HospitalPharmacy
- 32. 5.5.2 RetailPharmacy
- 33. 5.5.3 OnlinePharmacy
- 34. 5.6. Market Analysis, Insightsand Forecast – By Region
- 35. 5.6.1 NorthAmerica
- 36. 5.6.2 Europe
- 37. 5.6.3 Asia Pacific
- 38. 5.6.4 LatinAmerica
- 39. 5.6.5 MiddleEast & Africa
- 40. 6. North AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 41. 6.1. Key Findings / Summary
- 42. 6.2. Market Analysis – By DrugClass
- 43. 6.2.1Immunomodulators
- 44. 6.2.2Interferons
- 45. 6.2.3Decarboxylase Inhibitors
- 46. 6.2.4 DopamineAgonists
- 47. 6.2.4 Others
- 48. 6.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 49. 6.3.1 MultipleSclerosis
- 50. 6.3.2Parkinson’s Disease
- 51. 6.3.3Alzheimer's Disease
- 52. 6.3.4 SpinalMuscular Atrophy (SMA)
- 53. 6.3.5 Others
- 54. 6.3. Market Analysis – By Routeof Administration
- 55. 6.4.1 Oral
- 56. 6.4.2Injection
- 57. 6.4.3Transdermal
- 58. 6.4. Market Analysis – ByDistribution Channel
- 59. 6.5.1 HospitalPharmacy
- 60. 6.5.2 RetailPharmacy
- 61. 6.5.3 Online Pharmacy
- 62. 6.5. Market Analysis – By Country
- 63. 6.6.1 U.S.
- 64. 6.6.2 Canada
- 65. 7. EuropeNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 66. 7.1. Key Findings / Summary
- 67. 7.2. Market Analysis – By DrugClass
- 68. 7.2.1Immunomodulators
- 69. 7.2.2Interferons
- 70. 7.2.3Decarboxylase Inhibitors
- 71. 7.2.4 DopamineAgonists
- 72. 7.2.4 Others
- 73. 7.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 74. 7.3.1 MultipleSclerosis
- 75. 7.3.2Parkinson’s Disease
- 76. 7.3.3Alzheimer's Disease
- 77. 7.3.4 SpinalMuscular Atrophy (SMA)
- 78. 7.3.5 Others
- 79. 7.4. Market Analysis – By Routeof Administration
- 80. 7.4.1 Oral
- 81. 7.4.2Injection
- 82. 7.4.3Transdermal
- 83. 7.5. Market Analysis – ByDistribution Channel
- 84. 7.5.1 Hospital Pharmacy
- 85. 7.5.2 RetailPharmacy
- 86. 7.5.3 OnlinePharmacy
- 87. 7.6. Market Analysis – ByCountries/ Sub regions
- 88. 7.6.1 U.K.
- 89. 7.6.2 Germany
- 90. 7.6.3 France
- 91. 7.6.4 Italy
- 92. 7.6.5 Spain
- 93. 7.6.6Scandinavia
- 94. 7.6.7 Rest ofEurope
- 95. 8. Asia PacificNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 96. 8.1. Key Findings / Summary
- 97. 8.2. Market Analysis – By DrugClass
- 98. 8.2.1Immunomodulators
- 99. 8.2.2Interferons
- 100. 8.2.3Decarboxylase Inhibitors
- 101. 8.2.4 DopamineAgonists
- 102. 8.2.4 Others
- 103. 8.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 104. 8.3.1 MultipleSclerosis
- 105. 8.3.2Parkinson’s Disease
- 106. 8.3.3Alzheimer's Disease
- 107. 8.3.4 SpinalMuscular Atrophy (SMA)
- 108. 8.3.5 Others
- 109. 8.4. Market Analysis – By Routeof Administration
- 110. 8.4.1 Oral
- 111. 8.4.2Injection
- 112. 8.4.3 Transdermal
- 113. 8.5. Market Analysis – ByDistribution Channel
- 114. 8.5.1 Hospital Pharmacy
- 115. 8.5.2 RetailPharmacy
- 116. 8.5.3 OnlinePharmacy
- 117. 8.6. Market Analysis – ByCountries/ Sub regions
- 118. 8.6.1 Japan
- 119. 8.6.2 China
- 120. 8.6.3 India
- 121. 8.6.4Australia
- 122. 8.6.5Southeast Asia
- 123. 8.6.6 Rest ofAsia Pacific
- 124. 9. Latin AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 125. 9.1. Key Findings / Summary
- 126. 9.2. Market Analysis – By DrugClass
- 127. 9.2.1Immunomodulators
- 128. 9.2.2Interferons
- 129. 9.2.3Decarboxylase Inhibitors
- 130. 9.2.4 DopamineAgonists
- 131. 9.2.4 Others
- 132. 9.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 133. 9.3.1 MultipleSclerosis
- 134. 9.3.2Parkinson’s Disease
- 135. 9.3.3Alzheimer's Disease
- 136. 9.3.4 SpinalMuscular Atrophy (SMA)
- 137. 9.3.5 Others
- 138. 9.4. Market Analysis – By Routeof Administration
- 139. 9.4.1 Oral
- 140. 9.4.2Injection
- 141. 9.4.3Transdermal
- 142. 9.5. Market Analysis – ByDistribution Channel
- 143. 9.5.1 HospitalPharmacy
- 144. 9.5.2 RetailPharmacy
- 145. 9.5.3 OnlinePharmacy
- 146. 9.6. Market Analysis – ByCountries/ Sub regions
- 147. 9.6.1 Brazil
- 148. 9.6.2 Mexico
- 149. 9.6.3 Rest ofLatin America
- 150. 10. Middle East &Africa Neurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026
- 151. 10.1. Key Findings / Summary
- 152. 10.2. Market Analysis – By DrugClass
- 153. 10.2.1Immunomodulators
- 154. 10.2.2 Interferons
- 155. 10.2.3Decarboxylase Inhibitors
- 156. 10.2.4Dopamine Agonists
- 157. 10.2.4 Others
- 158. 10.3. Market Analysis, Insightsand Forecast – By Disease Indication
- 159. 10.3.1Multiple Sclerosis
- 160. 10.3.2Parkinson’s Disease
- 161. 10.3.3Alzheimer's Disease
- 162. 10.3.4 SpinalMuscular Atrophy (SMA)
- 163. 10.3.5 Others
- 164. 10.4. Market Analysis – By Routeof Administration
- 165. 10.4.1 Oral
- 166. 10.4.2Injection
- 167. 10.4.3Transdermal
- 168. 10.5. Market Analysis – ByDistribution Channel
- 169. 10.5.1Hospitals
- 170. 10.5.2 RetailPharmacy
- 171. 10.5.3 OnlinePharmacy
- 172. 10.6. Market Analysis – ByCountries/ Sub regions
- 173. 10.6.1 SouthAfrica
- 174. 10.6.2 GCC
- 175. 10.6.3 Rest ofMiddle East & Africa
- 176. 11. CompetitiveAnalysis
- 177. 11.1. Key Industry Developments
- 178. 11.2. Global Market ShareAnalysis (2018)
- 179. 11.3. Competition Dashboard
- 180. 11.4. Comparative Analysis –Major Players
- 181. 11.5. Company Profiles (Overview,Drug Classs & services, SWOT analysis, Recent developments, strategies,financials (based on availability))
- 182. 11.5.1 Biogen
- 183. 11.5.2 Pfizer,Inc.
- 184. 11.5.3 F.Hoffmann-La Roche Ltd
- 185. 11.5.4 Merck& Co., Inc.
- 186. 11.5.5Novartis AG
- 187. 11.5.6 Sanofi
- 188. 11.5.7 TevaPharmaceutical Industries Ltd.
- 189. 11.5.8 OrionPharma
- 190. 11.5.9 UCB S.A
- 191. 11.5.10 ACADIAPharmaceuticals Inc.
- 192. 11.5.11 H.Lundbeck A/S
- 193. 11.5.12Mitsubishi Tanabe Pharma Corporation
- 194. 11.5.13 OtherProminent Players
- 195. 12. StrategicRecommendations "
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook